Welcome to our dedicated page for Agilon Health news (Ticker: AGL), a resource for investors and traders seeking the latest updates and insights on Agilon Health stock.
The agilon health, inc. (AGL) news page on Stock Titan aggregates company-specific updates for investors and observers who follow its role in value-based healthcare. agilon health describes itself as a trusted partner empowering physicians to transform health care in their communities, and its news flow reflects this focus on physician partnerships and senior care.
Company announcements commonly cover financial results, including quarterly earnings releases that discuss membership on the agilon platform, revenue from medical services, and performance within its value-based care arrangements. These releases often provide detail on metrics related to Medicare Advantage members and other value-based models for senior patients.
agilon health news also includes items on leadership and governance, such as changes in executive roles, the establishment of an Office of the Chairman, and updates on board-level decisions. In addition, the company frequently announces participation in healthcare and investor conferences, where its management team discusses the business, its Total Care Model, and its value-based care strategy.
Another recurring theme in agilon health’s news is research related to value-based care. The company has highlighted studies examining how its model may relate to clinical and quality outcomes, healthcare utilization, and access to primary care for Medicare patients. These research-focused releases describe how physicians working within agilon’s value-based care framework manage senior patients and how payment models may influence practice patterns.
Visitors to this page can review these types of updates in one place, from earnings announcements and NYSE compliance notices to conference appearances and research publications connected to agilon health’s value-based Total Care Model for senior patients.
agilon health (NYSE: AGL) reported Q4 2025 revenue of $1.57B (+3% YoY) and fiscal 2025 revenue of $5.93B (-2% YoY). The company posted a Q4 net loss of $189M and FY net loss of $391M, with FY Adjusted EBITDA loss of $296M. Total members declined to 625,000. Cash and marketable securities were $285M with total debt of $35M. 2026 guidance targets revenue of $5.41–$5.58B, medical margin $300–$350M and Adjusted EBITDA range implying a mid‑point around breakeven.
agilon health (NYSE: AGL) announced management will participate in three investor conferences in March 2026: Cowen on March 2, Jefferies on March 9, and Barclays on March 10. Webcasts will be available for Cowen and Barclays; Jefferies will not provide a webcast due to event format.
Replays and on‑demand audio will be posted in the company’s Events & Presentations section on its investor relations website shortly after each presentation.
agilon health (NYSE: AGL) will release its fourth quarter and full year 2025 financial results after market close on Wednesday, February 25, 2026. The company will host a conference call at 4:30 p.m. ET the same day to discuss results. U.S. participants can dial (833) 470-1428, international participants +1 (404) 975-4839, using participant code 868078. A simultaneous webcast will be available in the Events & Presentations section of agilon's investor relations website at https://investors.agilonhealth.com, and a replay will be posted for on-demand listening shortly after the call.
agilon health (NYSE: AGL) said its management team will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Tuesday, December 2, 2025 at 3:00 PM ET. Investors can listen via a simultaneous webcast on the company’s Events & Presentations page at the investor relations website. Replays will be posted for on-demand listening shortly after the presentation.
agilon health (NYSE: AGL) announced on November 7, 2025 that the New York Stock Exchange issued a notice dated November 5, 2025 saying the company is no longer in compliance with the NYSE continued listing Price Criteria because the average closing price was under $1.00 over a consecutive 30 trading-day period ended November 4, 2025.
The notice does not have immediate impact on the listing, and the company said operations and SEC reporting are not anticipated to be affected. agilon intends to notify the NYSE by November 19, 2025 that it will remain listed and plans to pursue a reverse stock split to regain compliance, subject to stockholder approval at the 2026 annual general meeting.
agilon health (NYSE: AGL) reported third-quarter 2025 results and re-established full-year outlook on November 4, 2025. Q3 revenue was $1.44B (down 1% YoY) with gross loss $68M, net loss $110M and Adjusted EBITDA loss $91M. Total members stood at 618,000 (6% decline YoY) including 503,000 Medicare Advantage and 115,000 ACO REACH beneficiaries.
The company cited a $73M shortfall in 2025 risk adjustment revenue (including a 9-month true-up), a $20M Q3 impact from exited markets and expects exited-market impact of $60M for the year. Cash and marketable securities were $311M and total debt $35M. Management expects $30M of operating cost reductions in 2026 and reiterated 2025 revenue guidance of $5.81B–$5.83B with Adjusted EBITDA of ($270M)–($245M).
agilon health (NYSE: AGL) will release third quarter 2025 financial results after market close on Tuesday, November 4, 2025 and host a conference call at 4:30 p.m. ET to discuss results.
U.S. participants can dial (833) 470-1428, international participants can dial +1 (404) 975-4839 and reference participant code 291396. A simultaneous webcast and on-demand replay will be available in the Events & Presentations section of agilon's investor relations website.
agilon health (NYSE: AGL) announced its management team will participate in a fireside chat at the 2025 Jefferies Healthcare Services Conference. The presentation is scheduled for Tuesday, September 30 at 8:45am ET.
Investors can access the live webcast through the "Events & Presentations" section of agilon health's investor relations website. On-demand replays will be made available shortly after the presentation concludes.
agilon health (NYSE: AGL) reported challenging second quarter 2025 results, with total revenue declining 6% year-over-year to $1.39 billion. The company experienced significant headwinds, including a $66 million prior period development impact and an $85 million reduction in risk adjustment revenue. Total platform membership decreased to 614,000, including 498,000 Medicare Advantage members.
The company reported a net loss of $104 million compared to a $31 million loss in Q2 2024, and negative medical margin of $53 million versus positive $106 million in the prior year. Following these results and a leadership change with CEO Steven Sell stepping down, agilon has suspended its full-year 2025 guidance. The company maintains a solid capital position with $327 million in cash and marketable securities.
agilon health (NYSE: AGL) announced a significant leadership transition as CEO Steven Sell steps down from his roles as President, CEO, and Board Director. Ronald A. Williams, the company's co-founder and Board Chairman since 2017, has been appointed Executive Chairman to lead the transition.
The Board has established an Office of the Chairman to manage interim operations and has initiated a search for a permanent CEO. The Office includes key executives such as the CFO, CMO, and other senior leaders. Additionally, the company has withdrawn its full year 2025 earnings guidance in conjunction with this leadership change.
Williams, a healthcare industry veteran and former Chairman and CEO of Aetna, will focus on driving operational improvements and supporting physician partners while the search for a new CEO is conducted.